"New Hope for Treatment-Resistant Depression: Guessing Right on Ketamine" - Joshua Gordon
In March 2019, the FDA approved a remarkable new medication – esketamine – which targets treatment-resistant depression. TRD is a form of depression that doesn’t get better even after the patient has tried at least two antidepressant therapies. Dennis Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and president of academic affairs for the Mount Sinai Health System made an educated guess: Let’s try glutamate. Dr. Charney noticed that a particular glutamate receptor blocker, ketamine, had profound psychological effects on people, inducing psychotic-like symptoms. The NIMH-funded Dr. Charney to continue his research at the Icahn School of Medicine at Mt. Sinai, to confirm that ketamine was useful in TRD, where it provides relief from depression in about half of patients.
— Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, President, Academic Affairs, Mount Sinai Health System
Mount Sinai Expands Psychedelic Research Center With New Facility in Upper Manhattan
Sep 19, 2024 View All Press Releases
Rachel Yehuda, PhD, Elected to National Academy of Medicine
Oct 21, 2019 View All Press Releases